Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT00683059
First received: May 21, 2008
Last updated: October 14, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2012
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):